MAP2K7 and neoplasm: The combination of inhibitors with the cytotoxic drugs led to a significant decrease in tumor cell viability when compared to the chemotherapeutic treatment in the absence of the MEK and DHCR7 inhibitors (Fig. 3G, Supplementary Fig. S10K, L).